The development of prognostic markers is particularly important in AML with normal cytogenetics (CN AML) and currently, three molecular markers (NPM1- and CEBPA mutations and FLT3 internal tandem duplication (FLT3-ITD)) are used in clinical practice [13]. The gene discussed is FLT3; the disease is acute myeloid leukemia.